We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

91 hedge funds and large institutions have $72.6M invested in Tetraphase Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 24

16% more call options, than puts

Call options by funds: $164K | Put options by funds: $141K

1% more funds holding

Funds holding: 9091 (+1)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

5% less capital invested

Capital invested by funds: $76.6M → $72.6M (-$4.02M)

Holders
91
Holders Change
+1
Holders Change %
+1.11%
% of All Funds
2.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
34
Reduced
24
Closed
14
Calls
$164K
Puts
$141K
Net Calls
+$23K
Net Calls Change
+$23K
Name Holding Trade Value Shares
Change
Change in
Stake
CI
51
Cigna Investments
Connecticut
$116K +$114K +1,444 New
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$115K +$316 +4 +0.3%
ARTA
53
A.R.T. Advisors
New York
$104K +$102K +1,295 New
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$103K +$88.9K +1,124 +1,022%
NFA
55
Nationwide Fund Advisors
Ohio
$98K +$1.27K +16 +1%
RFCA
56
R&F Capital Advisors
New York
$96K +$94.1K +1,189 New
CS
57
Credit Suisse
Switzerland
$93K -$86.4K -1,092 -48%
OAM
58
Oxford Asset Management
United Kingdom
$90K +$88.2K +1,115 New
AIG
59
American International Group
New York
$84K -$237 -3 -0.3%
Squarepoint
60
Squarepoint
New York
$83K +$81.7K +1,033 New
State Board of Administration of Florida Retirement System
61
State Board of Administration of Florida Retirement System
Florida
$79K
BA
62
BlackRock Advisors
Delaware
$76K -$1.98K -25 -3%
Tudor Investment Corp
63
Tudor Investment Corp
Connecticut
$74K +$8.46K +107 +13%
VOYA Investment Management
64
VOYA Investment Management
Georgia
$70K
T. Rowe Price Associates
65
T. Rowe Price Associates
Maryland
$68K -$396 -5 -0.6%
UBS Group
66
UBS Group
Switzerland
$68K +$42.2K +534 +172%
MCM
67
Manchester Capital Management
Vermont
$60K +$29.6K +374 +100%
TCM
68
Teza Capital Management
Illinois
$58K +$56.8K +718 New
Citadel Advisors
69
Citadel Advisors
Florida
$54K -$48.2K -609 -48%
Legal & General Group
70
Legal & General Group
United Kingdom
$51K +$27.1K +342 +125%
JP Morgan Chase
71
JP Morgan Chase
New York
$49K +$44.4K +561 +1,058%
Bank of America
72
Bank of America
North Carolina
$48K +$16.7K +211 +55%
Two Sigma Investments
73
Two Sigma Investments
New York
$47K +$45.7K +578 New
PCM
74
Parsons Capital Management
Rhode Island
$44K +$43.5K +550 New
BlackRock
75
BlackRock
New York
$30K -$2.53K -32 -8%

TTPH Hedge Fund Activity: Q4 2016 in Review

91 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q4 2016, worth a combined $72.6M — down 5.3% from $76.6M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new TTPH positions and 14 closed out — a net gain of 1 holder — while 34 added to existing stakes and 24 trimmed.

The largest buyer was Dimensional Fund Advisors, adding an estimated $763K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.54M sold.

  • 91 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q4 2016, up from 90 in Q3 2016.
  • Funds reported $72.6M of Tetraphase Pharmaceuticals, Inc. stock for Q4 2016, down 5.3% quarter-over-quarter.
  • 15 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q4 2016 and 14 closed out, a net change of +1 holder.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q4 2016 was Dimensional Fund Advisors, an estimated $763K added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q4 2016 was Armistice Capital, an estimated $2.54M sold.

Based on aggregated 13F filings for Q4 2016.